ECTRIMS 2021 | How do we move sNfL into clinical practice?
Neurofilament light (NfL) is the most promising candidate blood-based biomarker for use in the routine management of multiple sclerosis (MS). The literature has robustly demonstrated the value of NfL measured in serum to predict future disease activity. Despite clear evidence, many challenges stand in the way of bringing a novel biomarker into a routine clinical setting. Jens Kuhle, MD, PhD, University Hospital and University of Basel, Basel, Switzerland, talks on the potential strategies to further the clinical development of serum NfL. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress 2021.
Disclosures
Jens Kuhle received speaker fees, research support, travel support, and/or served on advisory boards for Swiss MS Society, Swiss National Research Foundation (320030_189140/1), University of Basel, Progressive MS Alliance, Bayer, Biogen, Celgene, Merck, Novartis, Octave Bioscience, Roche, Sanofi.
